AMES, Iowa, July 22, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease products to improve the lives of patients, today announced that Dr. Thomas Monath has received the James H. Steele Gold-Headed Cane Award of the American Veterinary Epidemiology Society (AVES). AVES presented this award at its annual convention in Boston on July 13 to recognize career accomplishments and achievements that significantly advance human health through veterinary epidemiology and public health.
Dr. Monath is Chief Scientific Officer and Chief Operating Officer of the Infectious Disease division of NewLink Genetics, where he is leading the development of an Ebola virus vaccine in partnership with Merck. This vaccine was initially developed by the Public Health Agency of Canada and was licensed by a subsidiary of NewLink Genetics in 2010.
Dr. Monath’s career in infectious disease began with 20 years of service at the U.S. Army Medical Research Institute of Infectious Diseases and the CDC’s Division of Vector-Borne Infectious Diseases. He then worked for more than 25 years in the healthcare biotechnology industry at PaxVax Inc., Hookipa Biotech AG, Juvaris Inc., Xcellerex Inc., Acambis Inc. and now NewLink. In these roles, he was involved in the development of a broad array of vaccines, including those for cholera, influenza, polio, malaria, HIV, anthrax, dengue, Japanese encephalitis, West Nile, yellow fever, C. difficile, smallpox and Ebola. He has served on numerous government and international committees on infectious diseases and biosecurity, World Health Organization (WHO) expert committees and the National Vaccines Advisory Committee (USA). He is on the editorial board of five scientific journals and has published approximately 400 papers and edited six books on viruses and vaccine development.
“We are proud of Dr. Monath’s many achievements and honored that he is leading our effort to bring our Ebola vaccine candidate forward,” said Dr. Charles Link, Jr., M.D., Chairman, CEO and Chief Scientific Officer of NewLink Genetics.
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve the lives of patients with cancer. Our portfolio of product candidates is poised to further cancer-treatment research. NewLink Genetics is actively researching a unique, multifaceted immuno-oncology treatment strategy based on its HyperAcute® Immunotherapies, which are designed to educate patients’ natural defenses to target cancer directly, and IDO Pathway Inhibitors, which prevent tumor cells from evading the immune response either alone or in combination with other treatment options. NewLink’s Ebola vaccine candidate is being tested in advanced clinical trials in Africa. For more information, please visit http://www.newlinkgenetics.com.
Corporate Contact: Jack Henneman Chief Financial Officer (515) 598-2561 Investor@newlinkgenetics.com Investor Contact: Donna LaVoie or Kristina Coppola LaVoieHealthScience (617) 374-8800, ext. 107/105 firstname.lastname@example.org email@example.com
Source:NewLink Genetics Corporation